Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12623001110673
Ethics application status
Approved
Date submitted
24/09/2023
Date registered
25/10/2023
Date last updated
4/04/2024
Date data sharing statement initially provided
25/10/2023
Type of registration
Prospectively registered
Titles & IDs
Public title
A Phase II, Multicenter, Double-Blinded, Randomized, Placebo-Controlled, Parallel-Group, Single-Dose Study to Determine the Safety, Preliminary Efficacy, and Pharmacokinetics of ARG-007 in Acute Ischemic Stroke Patients
Query!
Scientific title
A Phase II, Multicenter, Double-Blinded, Randomized, Placebo-Controlled, Parallel-Group, Single-Dose Study to Determine the Safety, Preliminary Efficacy, and Pharmacokinetics of ARG-007 in Acute Ischemic Stroke Patients
Query!
Secondary ID [1]
309690
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SEANCON
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Stroke
330066
0
Query!
Acute
331700
0
Query!
Condition category
Condition code
Stroke
326967
326967
0
0
Query!
Ischaemic
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - ARG-007
Experimental: ARG-007 - Single intravenous infusion of ARG-007 0.3 mg/kg over 10 minutes, administered in hospital by registered nurse. Participants are to be administered the ARG-007 as soon after randomization as possible but before the completion of endovascular revascularization (using mechanical thrombectomy with or without thrombolysis).
Participants will be followed up in hospital on Day 2, Day 3, Day 6 (or Discharge), Safety assessments including vital signs, NIHSS and laboratory will be carried out during these visits. Additionally, an NCCT will be performed at day 2 and an MRI at day 3.
Following discharge participants will be followed up by telephone on Day 30, and Day 90 (End of Study [EoS]). Questionnaires will be collected during these visits to assess safety & efficacy.
Query!
Intervention code [1]
326132
0
Treatment: Drugs
Query!
Comparator / control treatment
Saline Placebo
There are no differences in procedures, activities, and/or processes between the intervention and placebo group.
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
334803
0
To evaluate the safety of a single dose of ARG-007 in participants with acute ischemic stroke (AIS).
The primary analyses will be mortality rate and frequency of AEs/SAEs.
Site personnel will collect AE information from participants. Open-ended
and nonleading questions will be used to enquire about any AEs/SAEs.
Query!
Assessment method [1]
334803
0
Query!
Timepoint [1]
334803
0
Day 1, Day 2, Day 3, Day 6 or Discharge, Day 30 and Day 90 (Primary timepoint).
Query!
Secondary outcome [1]
422346
0
The efficacy analysis is the difference in infarct volume between the ARG-007 and placebo groups as measured by MRI (or NCCT if MRI is not available) at 48 hours (Day 3 ± 1 day).
Query!
Assessment method [1]
422346
0
Query!
Timepoint [1]
422346
0
Day 3 post-intervention.
Query!
Eligibility
Key inclusion criteria
1) Diagnosis of AIS deemed suitable for endovascular revascularization (mechanical thrombectomy with or without a thrombolytic agent).
2) Aged >/= 18 years.
3) Stroke onset (last known well) time < /= 24 hours before randomization.
4) The National Institutes of Health Stroke Scale (NIHSS) >/= 5 points at time of randomization.
5) Pre-stroke modified Rankin Score (mRS) < /= 3. Participant must have been living in their own home, apartment, or a senior’s lodge where no nursing care is required.
6) Confirmed symptomatic intracranial occlusion, based on computed tomographic angiography (CTA), at one or more of the following locations: intracranial internal carotid artery (T/L morphology) or M1 middle cerebral artery.
7) For participants transferring to stroke center from another hospital, CTA for study eligibility is to be performed or repeated at stroke center with endovascular suite onsite if there is a long delay (> 6 hours) from time of first CTA to time of repeat CTA.
8) Signed informed consent from participant or their legally authorized representative, or if required to enable inclusion by applicable national laws and regulations and the applicable Institutional Review Board/Ethics Committee requirements for obtaining consent from the investigator after consultation with an independent physician who is not otherwise participating in the study.
9) Willing (participant and/or caretaker) to commit to follow up assessments.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1) Evidence of a large core of established infarction defined as ASPECTS of 0 to 5.
2) Evidence of intracranial hemorrhage or mass lesion on the qualifying imaging.
3) Endovascular revascularization procedure has already been completed at the time of Screening/randomization or has been completed before administration of study drug.
4) Planned use of an endovascular device that is not approved or does not have clearance by the relevant regulatory authority.
5) Rapid spontaneous improvement of neurological signs during Screening, as defined by a reduction of >/= 8 on the NIHSS between onset of symptoms and randomization.
6) History of stroke (ischemic or hemorrhagic) or penetrating head injury within 90 days before enrollment.
7) Uncontrolled blood pressure (BP) >/= 180/110 mmHg before endovascular revascularization procedure is initiated.
8) No femoral pulses, very difficult endovascular access, or extreme tortuosity of the great vessels that is predicted to result in an inability to timely deliver endovascular therapy. Direct common carotid or radial/brachial/axillary access is permissible.
9) Estimated or known body weight < 45 kg or > 130 kg.
10) Pregnancy: If a woman is of childbearing potential and has a positive point-of-care urine beta-human chorionic gonadotropin (ß-HCG) test or is breastfeeding.
11) Severe known renal impairment defined as requiring dialysis (hemo- or peritoneal) or a creatinine clearance < 29 mL/min.
12) Severe or fatal comorbid illness that will prevent improvement or follow-up.
13) Cannot complete follow-up visits because participant is a visitor to the area, or any other known reason that would prevent attendance at follow-up visits.
14) Received treatment with an investigational drug or device within 30 days before enrollment.
15) Any other condition that, in the opinion of the investigator, may adversely affect the safety of the participant, the participant’s ability to complete the study, or the outcome of the study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
13/03/2024
Query!
Actual
28/03/2024
Query!
Date of last participant enrolment
Anticipated
31/10/2025
Query!
Actual
Query!
Date of last data collection
Anticipated
30/01/2026
Query!
Actual
Query!
Sample size
Target
92
Query!
Accrual to date
3
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA,VIC
Query!
Recruitment hospital [1]
24857
0
The Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [2]
24858
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment hospital [3]
24859
0
Monash Medical Centre - Clayton campus - Clayton
Query!
Recruitment hospital [4]
24860
0
Fiona Stanley Hospital - Murdoch
Query!
Recruitment hospital [5]
24861
0
Sir Charles Gairdner Hospital - Nedlands
Query!
Recruitment hospital [6]
24862
0
John Hunter Hospital - New Lambton
Query!
Recruitment hospital [7]
24863
0
Liverpool Hospital - Liverpool
Query!
Recruitment hospital [8]
25078
0
Royal Melbourne Hospital - Royal Park campus - Parkville
Query!
Recruitment hospital [9]
26371
0
Royal Brisbane & Womens Hospital - Herston
Query!
Recruitment hospital [10]
26372
0
Gold Coast University Hospital - Southport
Query!
Recruitment postcode(s) [1]
40505
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
40506
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [3]
40507
0
3168 - Clayton
Query!
Recruitment postcode(s) [4]
40508
0
6150 - Murdoch
Query!
Recruitment postcode(s) [5]
40509
0
6009 - Nedlands
Query!
Recruitment postcode(s) [6]
40510
0
2305 - New Lambton
Query!
Recruitment postcode(s) [7]
40511
0
2170 - Liverpool
Query!
Recruitment postcode(s) [8]
40748
0
3050 - Royal Melbourne Hospital
Query!
Recruitment postcode(s) [9]
42343
0
4029 - Herston
Query!
Recruitment postcode(s) [10]
42344
0
4215 - Southport
Query!
Funding & Sponsors
Funding source category [1]
313938
0
Commercial sector/Industry
Query!
Name [1]
313938
0
Argenica Therapeutics Ltd
Query!
Address [1]
313938
0
4/117 BroadwayNedlands WA 6009, Australia
Query!
Country [1]
313938
0
Australia
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Argenica Therapeutics Ltd
Query!
Address
4/117 BroadwayNedlands WA 6009, Australia
Query!
Country
Australia
Query!
Secondary sponsor category [1]
315897
0
None
Query!
Name [1]
315897
0
Query!
Address [1]
315897
0
Query!
Country [1]
315897
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
313031
0
St. Vincent’s Hospital (Melbourne) Human Research Ethics Committee
Query!
Ethics committee address [1]
313031
0
41 Victoria Parade, Fitzroy, VIC 3065
Query!
Ethics committee country [1]
313031
0
Australia
Query!
Date submitted for ethics approval [1]
313031
0
18/07/2023
Query!
Approval date [1]
313031
0
11/09/2023
Query!
Ethics approval number [1]
313031
0
Query!
Summary
Brief summary
The primary purpose of this single dose study is to assess the safety and preliminary efficacy of ARG-007 in participants with AIS undergoing endovascular revascularization.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
126746
0
Prof Graeme Hankey
Query!
Address
126746
0
Perron Institute Chair in Stroke Research, RR Block, QE II Medical Centre, 8 Verdun St, Nedlands, WA 6009
Query!
Country
126746
0
Australia
Query!
Phone
126746
0
+61 8 6151 0828
Query!
Fax
126746
0
Query!
Email
126746
0
[email protected]
Query!
Contact person for public queries
Name
126747
0
Dr Meghan Thomas
Query!
Address
126747
0
Argenica Therapeutics Ltd, 4/117 Broadway Nedlands WA 6009, Australia PO Box 1458, West Perth WA 6872
Query!
Country
126747
0
Australia
Query!
Phone
126747
0
+61 8 9329 3396
Query!
Fax
126747
0
Query!
Email
126747
0
[email protected]
Query!
Contact person for scientific queries
Name
126748
0
Dr Meghan Thomas
Query!
Address
126748
0
Argenica Therapeutics Ltd, 4/117 Broadway Nedlands WA 6009, Australia. PO Box 1458, West Perth WA 6872
Query!
Country
126748
0
Australia
Query!
Phone
126748
0
+61 8 9329 3396
Query!
Fax
126748
0
Query!
Email
126748
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF